

February 1, 2015

CURRICULUM VITAE

A. PERSONAL INFORMATION

Name in Full: David Fredrick Penson, M.D., M.P.H., M.M.H.C.
Business Address: A-1302 Medical Center North (2765)
1161 21st Avenue South
Nashville, Tennessee 37232-2765
Business Phone: (615) 343-0234
Business Fax: (615) 322-8990
E-mail Address: david.penson@vanderbilt.edu

B. EDUCATION

High School: Friends Academy, Locust Valley, NY, 1983
College: University of Pennsylvania, B.A., 1987
Medical School: Boston University School of Medicine, MD, 1991
Graduate School: Yale University School of Public Health, MPH, 2001
Vanderbilt University, Owens Graduate School of Management,
Master of Management in Healthcare, 2014
Internship: University of California, Los Angeles Center for Health
Sciences, July 1991-June 1992, General Surgery
Residencies: University of California, Los Angeles Center for Health
Sciences, July 1992-June 1993, General Surgery
University of California, Los Angeles Center for Health
Sciences, July 1993-June 1997, Urology
Fellowship: Robert Wood Johnson Clinical Scholars Program, Yale
University School of Medicine, July 1997-June 1999, Clinical
Epidemiology and Health Services Research
Licensure: California, 1992 (Certificate # G75971, exp. 12/31/14)
Tennessee, 2009 (Certificate # 45072, exp 12/31/15)
U.S. DEA, 1992 (Certificate # BP3568106, exp. 3/31/14)
Board Certification: Diplomate, National Board of Medical Examiners #399905
July, 1992
Diplomate, American Board of Urology, February, 2001,
(expires Feb 2021)

C. PROFESSIONAL BACKGROUND

Academic Appointments

Staff Urologist, VA Connecticut Health Care System	1997-2009
Staff Urologist, VA Puget Sound Health Care System	1999-2003
Assistant Professor of Urology, Univ. of Washington,	1999-2003
Adjunct Asst. Professor of Health Services, Univ. of Washington	2000-2003

Affiliate Investigator, Fred Hutchinson Cancer Research Center	1999-2008
Visiting Associate Professor of Urology and Preventive Medicine Keck School of Medicine, University of Southern California	2004-2007
Associate Professor of Urology and Preventive Medicine Keck School of Medicine, University of Southern California	2007-2009
Staff Physician, VA Tennessee Health Care System	2009-present
Faculty, VA Tennessee Valley Geriatric Research, Education, and Clinical Center (GRECC)	2009-present
Professor of Urologic Surgery and Medicine, Vanderbilt University	2009-present
Director, Center for Surgical Quality and Outcomes Research Vanderbilt University Medical Center	2009-present
Professor of Health Policy, Vanderbilt University	2014-present
Chairman, Department of Urologic Surgery	2015-present

Honors and Awards

American Urological Association (AUA)-Western Section Resident Scholarship Award	1995
Miley B. Wesson/Proctor and Gamble Resident Essay Contest, First Place American Urological Association-Western Section	1996
Robert Wood Johnson Clinical Scholar, Yale University	1997-1999
American Foundation for Urologic Disease Health Services Research Scholar	1998-2000
Ambrose/Reed Socioeconomic Essay Contest, First Place American Urological Association	2001
VA HSR&D Career Development Award, Level I	2001-2004
AUA/EAU Academic Fellowship European Exchange Program, Fellow	2002
AUA Gold Cystoscope Award	2006
AUA G. James Gallagher Health Policy Scholar	2007-2008
Ingram Professor of Cancer Research	2011-2013
Member, American Association of Genitourinary Surgeons	2012-present
Hamilton and Howd Chair in Urologic Oncology	2013-present

Specific Teaching Responsibilities

Director, Urology section, Human Biology 562 course for second year medical students, University of Washington School of Medicine	2001-2003
Co-director, Urology Residency Program, University of Washington School of Medicine	2001-2002
Lecturer on prostate cancer, third year medical student surgical Rotation, Keck School of Medicine, USC	2004-2009
Lecturer on clinical research methods, urology residency program Keck School of Medicine, USC	2004-2009
Lecturer on erectile dysfunction, second year medical student reproductive medicine course, Keck School of Medicine, USC	2007-2009
Course Director, Clinical Economics and Decision Analysis, Masters in Public Health Program, Vanderbilt University School of Medicine	2010-present

Specific administrative responsibilities

Biomedical scientific review subcommittee, VA Puget Sound Health Care System	2000-2002
Health Services Research Review Subcommittee, VA Puget Sound Health Care System	1999-2003
Co-director, Surgical Outcomes Assessment and Research Group, Univ. of Washington	1999-2002
Bioinformatics Working Group, USC/Norris CCC	2004-2009
Health Sciences Institutional Review Board II, USC HSC	2005-2006
Executive Committee, Institute for Medicine and Public Health, Vanderbilt University Medical Center	2009-present
Scientific Review Committee, Vanderbilt CTSA	2011-2013
Vanderbilt Physician-Scientist Development Award review committee	2011-2013
Vanderbilt Medical Scholars Program Advisory board	2012-present
Co-leader, Cancer Control and Health Outcomes Program Vanderbilt-Ingram Cancer Center	2013-present
Medical Director, Vanderbilt Urology Clinic	2013-present
Member, Adult Enterprise Quality Committee, Vanderbilt University	2014-present

Other Academic Activities

Review Panel for NIDDK Minimally Invasive Therapies for Benign Prostatic Hyperplasia Clinical Trial Consortium	2001
Participant of the Kidney/Bladder Cancers Progress Review Group (PRG), National Cancer Institute	2002
Review panel for NIDDK Complementary and Alternative Medicine For Benign Prostatic Hyperplasia Clinical Trial Consortium	2003
Lecturer, NIH/NIDDK course on “Starting an Academic Career in Adult and Pediatric Urology and Nephrology”	2004
Participant of the Pediatric Urology Progress Review Group (PRG), National Institute for Diabetes, Digestive and Kidney Diseases	2005
Director, Postgraduate educational course on Clinical Trials for Urologists, AUA Annual National Meeting	2004-2007
Abstract Review Committee for AUA Annual National Meeting	2004-present
Chairman, Data Safety and Monitoring Board, VA Cooperative Study #553: Chemotherapy after Prostatectomy (CaP) for High-Risk Prostate Carcinoma: A phase III randomized study.	2006-2013
Co-Chairman, American Urological Association Foundation/Society of Basic Urologic Research Annual Research Meeting	2007
Lecturer, Postgraduate educational course on Pay-for-Performance for Urologists, AUA Annual National Meeting	2008-2011
<i>Ad Hoc</i> reviewer, Health Services Organization and Delivery Study Section, NIH CSR	2008-2011
Reviewer, AHRQ Special Emphasis for iADAPT award	2010
Member, Health Services Organization and Delivery Study Section NIH CSR	2011-2014
<i>Ad Hoc</i> member, Oncology Drugs Advisory Committee	2010-2012

Food and Drug Administration Member, VA Health Services Research and Development Career Award Review Panel	2012-2014
Chair, Health Services Organization and Delivery Study Section NIH CSR	2014-present

Committee memberships

National/International

GU Organ Committee, American College of Surgeons Oncology Group	2000-2002
Auditing Committee, American College of Surgeons Oncology Group	2001-2005
Chairman, GU Organ Committee, American College of Surgeons Oncology Group	2002-2005
Blue Ribbon Panel on Radical Prostatectomy Outcomes, American Urological Association	2004-2005
Quality Improvement and Patient Safety Committee, American Urological Association	2003-2006
Chairman, Quality Improvement and Patient Safety Committee, American Urological Association	2006-2008
<i>Ad Hoc</i> member, Practice Guidelines Committee, American Urological Association	2005-present
American Urological Association/American Board of Urology Examination Committee	2006-2009
Chairman, Pay for Performance Taskforce, American Urological Association	2006-2008
Health Policy Council, American Urological Association	2007-2008
Vice Chairman, Health Policy Council, American Urological Association	2008-2012
AUA liaison, Commission on Cancer, American College of Surgeons	2007-2011
AUA representative, National Quality Forum (NQF)	2008-2011
Member, NQF Surgical Technical Panel	2009-2010
Member, NQF Patient Outcomes Cancer Technical Advisory Panel	2009-2010
Member, NQF Efficiency Resource Use Steering Committee	2010-2012
Chairperson, NQF Efficiency Resource Use Cancer Technical Advisory Panel	2010-2012
Member, National Advisory Council, U.S. Agency for Healthcare Quality and Research	2012-2014
Chairman, Health Policy Council, American Urological Association	2012-2014
American Board of Urology Oral Examiner	2014-present
Chairman, Public Policy & Practice Support Council, American Urological Association	2014-present

Local/Regional

Executive Committee, Washington State Urologic Association	2002-2004
--	-----------

Alternate representative (District 6), AUA Western Section Board of Directors	2005-2007
Nominating Committee, AUA Western Section	2006-2007
District 6 representative, AUA Western Section Board of Directors	2008-2009

Society Memberships

Local/Regional

Southeastern Section, American Urological Association
Western Urologic Forum

National/International

American Urological Association
American College of Surgeons Oncology Group
Southwestern Oncology Group
Sexual Medicine Society of North America
Society of Urologic Oncology
Society for Urologic Research
International Society for Impotence Research
American Society of Clinical Oncology
Fellow, American College of Surgeons
Society for Medical Decision Making
Urologic Research Society
AcademyHealth
American Public Health Association
American Medical Association

Consultantships

Editorial Board Memberships

MEDSCAPE Urology	2000-2006
American Journal of Urology Review	2002-2007
Current Sexual Health Reports	2003-2009
DiseaseDEX, Thomson Micromedex	2003-2006
International Journal of Impotence Research	2004-present
Editor, Outcomes Research Topics, Urologic Oncology	2005-2009
Survey Section, Urologic Oncology	2006-2008
Journal of Clinical Oncology	2007-2009
Urologic Survey, Journal of Urology	2007-present
Advances in Urology	2009-2011
Editor, Health Policy Topics, Urologic Oncology	2009-present
AUA Update Series	2011-present
World Journal of Urology	2011-present
Clinical Investigation	2011-present
Journal of Comparative Effectiveness	2012-present
Seminars in Urologic Oncology	2013-present

Reviewer/Consultant for

Journal of Urology
Urology
BJU International
European Urology
Journal of Clinical Oncology
Cancer
Urologic Oncology
Annals of Internal Medicine
Journal of the American Medical Association
Cancer, Epidemiology Biomarkers and Prevention
Quality of Life Research
Medical Care
Journal of General Internal Medicine
Archives of Internal Medicine
Prostate Cancer and Prostate Diseases
The Prostate
Journal of the National Cancer Institute
American Journal of Epidemiology
Journal of Clinical Epidemiology
International Journal of Impotence Research
Journal of Sexual Medicine
Journal of Health Care for the Poor and Underserved
JAMA
New England Journal of Medicine
Health Affairs
HSR

D. FEDERALLY FUNDED RESEARCH ACTIVITIES

- *Surveillance Modeling of Racial Disparities in US Prostate Cancer Trends (CISNET)*
NIH/NCI U01 CA088160-05
2000-10, Co-Investigator (5% effort)
- *Long-Term Quality of Life of Prostate Cancer Survivors*
NIH/NCI, 1 R01 CA098430-01
2004-7, Principal Investigator (15% effort)
- *A Prospective Study of Decision Making for Localized Prostate Cancer (The FACTS study)*
CDC, 3 U48 DP000050-01S1
2004-7, Principal Investigator (5%, Administered through UW SIP)
- *Improving Outcomes in the Cancer Registry Data: A Feasibility Study*
NIH/NCI SEER Special Study
2005-7, Co-Principal Investigator (3% effort)

- *Race, Comorbidity & Long Term Prostate Cancer Outcomes*
NIH/NCI 1R01CA114524-01A2
2007-2011, Principal Investigator (20% effort)
- *2007 AUA/SBUR Summer Research Conference "Clinical Trials and Outcomes Research"*
NIH/NIDDK 1 R13 DK080626-01
2007, Principal Investigator (2% contributed effort)
- *Outcomes-based guideline development for prostate cancer screening and treatment*
NIH/NCI 1R01 CA131874
2008-2013 Co-Investigator (5% effort)
- *American Recovery and Reinvestment Act of 2009: Comprehensive EPC Comparative Effectiveness Reviews for Effective Health Care*
HHS/AHRQ 290-2007-10065-I (Task Order No. 5)
2009-2012, Core faculty (6% effort)
- *Comparative Effectiveness of Treatments for Localized Prostate Cancer*
HHS/AHRQ 1 R01 HS019356-01
2010-2013, Principal Investigator (35% effort)
- *Long-term Follow-up of the Family And Cancer Therapy Selection (FACTS) Study*
CDC 5U48DP001911-03
2012-2014, Co-investigator (5% effort)
- *Generating Critical Patient-Centered Information for Decision Making in Localized Prostate Cancer*
Patient-Centered Outcomes Research Institute CE-12-11-4667
2013-2016, Principal Investigator (20% effort)
- *Comparative Effectiveness of Modern Therapies for Localized Prostate Cancer*
HHS/AHRQ 1R01HS022640-01
2013-2018, Principal Investigator (10% effort)
- *Prostate Modeling to Identify Surveillance Strategies (PROMISS)*
NIH/NCI R01CA183570-01
2013-2018, Co-Principal Investigator (15% effort)
- *The Vanderbilt PCOR Career Knowledge, Education and Training Program*
AHRQ 1K12HS022990
2014-19, Principal Investigator (10% effort)

E. TRAINEES MENTORED

- Steven Zeliadt, PhD, post-doctoral health services research fellow, 2000-2003
- Lora Plaskon, MD, MSE, urology research resident, 2001-2002
- Michael Porter, MD, MPH, urology research resident and post-doctoral fellow, 2002-2004
- Peter Black, MD, urology research resident, 2002-2003
- Jeremy Hanson, MD, medical student, 2004-2005
- Elena Miller, MD, medical student, 2006-2007
- David Etzioni, MD, MPH, general surgery junior faculty, 2006-2009
- George Huang, MD, post-doctoral urology fellow, 2006-2007
- H. Max Bruins, BA, medical student, 2007-2009
- Georg Bartsch, MD, post-doctoral urology fellow, 2008-2009
- Danil Makarov, MD, post-doctoral urology fellow and junior faculty, 2007-2012
- Daniel Barocas, MD, MPH, post-doctoral urology fellow and junior faculty, 2009-present
- Eric Grogan, MD, MPH, thoracic surgery junior faculty, 2009-present
- Ben Poulouse, MD, MPH, general surgery junior faculty, 2009-present
- Priya Padmanabhan, MD, MPH, post-doctoral urology fellow, 2009-2010
- Matthew McGirt, MD, neurosurgery junior faculty, 2010-2013
- W. Stuart Reynolds, MD, urology junior faculty, 2010-present
- Robert Kavitt, MD, post-doctoral gastroenterology fellow, 2010-2012
- Alexander Parikh, MD, MPH, general surgery junior faculty, 2010-2011
- Brad Hill, BA, medical student, 2010-2011
- Christopher Anderson, MD, urology research resident, 2010-2013
- Kristin Archer Swygert, PhD, Orthopedic surgery junior faculty, 2010-present
- Rebecca Snyder, MD, general surgery research resident, 2011-2013
- Matthew Resnick, MD, post-doctoral urology fellow and junior faculty, 2011-present
- David Francis, MD, otolaryngology junior faculty, 2011-present
- Alicia Morgans, MD, medical oncology junior faculty, 2012-present
- William Sohn, MD, post-doctoral urology fellow, 2013-present
- Brock O'Neil, MD, post-doctoral urology fellow, 2014-present

F. BIBLIOGRAPHY

PEER REVIEWED

Original Reports

1. Bassett JC, Gore JL, Kwan L, Ritch CR, Barocas DA, **Penson DF**, McCarthy WJ, Saigal CS. Knowledge of the harms of tobacco use among patients with bladder cancer. *Cancer*. 2014 Dec 15;120(24):3914-22. doi: 10.1002/cncr.28915. Epub 2014 Nov 10. PMID: 25385059
2. Bassett JC, Alvarez J, Koyama T, Resnick M, You C, Ni S, **Penson DF**, Barocas DA. Gender, Race, and Variation in the Evaluation of Microscopic Hematuria

- Among Medicare Beneficiaries. *J Gen Intern Med.* 2014 Dec 2. [Epub ahead of print] PMID: 25451992
3. Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Resnick MJ, Barocas DA, **Penson DF**. Influence of Age on Incident Diabetes and Cardiovascular Disease in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy. *J Urol.* 2014 Nov 11. pii: S0022-5347(14)04835-6. doi: 10.1016/j.juro.2014.11.006. [Epub ahead of print] PMID: 25451829
 4. Kummerow KL, Du L, **Penson DF**, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. *JAMA Surg.* 2015 Jan 1;150(1):9-16. doi: 10.1001/jamasurg.2014.2895. PMID: 25408966
 5. Tsai H-T, **Penson D**, Luta G., Lynch J., Zhou Y., and Potosky A., Adoption of Intermittent Androgen Deprivation Therapy in Advanced Prostate Cancer: A Population-based Study in US Urology Practice, *Urology Practice* (in press).
 6. Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, Herrell SD, **Penson DF**, Resnick MJ, Smith JA, Clark PE. Renal cell cancer histologic subtype distribution differs by race and sex. *BJU Int.* 2014 Oct 13. doi: 10.1111/bju.12950. [Epub ahead of print] PMID:25307281
 7. Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Litwin MS, **Penson DF**. Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study. *Urology.* 2015 Jan;85(1):92-100. doi: 10.1016/j.urology.2014.07.003. Epub 2014 Sep 26. PMID: 25261048
 8. Ritch CR, Graves AJ, Keegan KA, Ni S, Bassett JC, Chang SS, Resnick MJ, **Penson DF**, Barocas DA. Increasing use of observation among men at low risk for prostate cancer mortality. *J Urol.* 2014 Sep 4. pii: S0022-5347(14)04357-2. doi: 10.1016/j.juro.2014.08.102. [Epub ahead of print] PMID: 25196658
 9. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, **Penson DF**. The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. *Eur Urol.* 2014 Aug 28. pii: S0302-2838(14)00788-X. doi: 10.1016/j.eururo.2014.08.035. [Epub ahead of print] PMID: 25174325
 10. Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, **Penson DF**. Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes

- study. *Prostate Cancer Prostatic Dis.* 2014 Dec;17(4):338-42. doi: 10.1038/pcan.2014.31. Epub 2014 Aug 19 PMID: 25134939
11. Reynolds WS, Ni S, Kaufman MR, **Penson DF**, Dmochowski RR. Trends in urodynamics in U.S. female medicare beneficiaries, 2000-2010. *Neurourol Urodyn.* 2014 Jun 29. doi: 10.1002/nau.22644. [Epub ahead of print] PMID: 24976252
 12. Ritch CR, Cookson MS, Chang SS, Clark PE, Resnick MJ, **Penson DF**, Smith JA Jr, May AT, Anderson CB, You C, Lee H, Barocas DA. Impact of Complications and Hospital-Free Days Following Radical Cystectomy on Health Related Quality of Life at 1 Year. *J Urol.* 2014 Nov;192(5):1360-4. doi: 10.1016/j.juro.2014.06.004. Epub 2014 Jun 10. PMID: 24928268
 13. Snyder RA, **Penson DF**, Ni S, Koyama T, Merchant NB. Trends in the use of evidence-based therapy for resectable gastric cancer. *J Surg Oncol.* 2014 Sep;110(3):285-90. doi: 10.1002/jso.23635. Epub 2014 May 30. PMID: 24891231
 14. Parikh AA, Robinson J, Zaydfudim VM, **Penson D**, Whiteside MA. The effect of health insurance status on the treatment and outcomes of patients with colorectal cancer. *J Surg Oncol.* 2014 Sep;110(3):227-32. doi: 10.1002/jso.23627. Epub 2014 May 9. PMID: 24810008
 15. Ritch CR, You C, May AT, Herrell SD, Clark PE, **Penson DF**, Chang SS, Cookson MS, Smith JA Jr, Barocas DA. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. *Urology.* 2014 Jun;83(6):1309-15. doi: 10.1016/j.urology.2014.02.023. Epub 2014 Apr 18. PMID: 24746665
 16. Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, **Penson DF**, Makarov DV. Twitter Response to the United States Preventive Services Task Force Recommendations against Screening with Prostate Specific Antigen. *BJU Int.* 2014 Mar 25. doi: 10.1111/bju.12748. [Epub ahead of print] PMID: 24661474
 17. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, **Penson DF**. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. *Cancer.* 2014 Apr 15;120(8):1263-71. doi: 10.1002/ncr.28563. Epub 2014 Feb 7. PMID: 24510400
 18. Friedlander DF, Resnick MJ, You C, Bassett J, Yarlagadda V, **Penson DF**, Barocas DA. Variation in the intensity of hematuria evaluation: a target for primary care quality improvement. *Am J Med.* 2014 Jul;127(7):633-640.e11. doi: 10.1016/j.amjmed.2014.01.010. Epub 2014 Jan 28. PMID: 24486290

19. Francis DO, Pearce EC, Ni S, Garrett CG, **Penson DF**. Epidemiology of Vocal Fold Paralysis after Total Thyroidectomy for Well-Differentiated Thyroid Cancer in a Medicare Population. *Otolaryngol Head Neck Surg*. 2014 Apr;150(4):548-57. doi: 10.1177/0194599814521381. Epub 2014 Jan 30. PMID:24482349
20. Francis DO, McKiever ME, Garrett CG, Jacobson B, **Penson DF**. Assessment of patient experience with unilateral vocal fold immobility: a preliminary study. *J Voice*. 2014 Sep;28(5):636-43. doi: 10.1016/j.jvoice.2014.01.006. Epub 2014 Apr 13. PMID: 24739444
21. Ramsey SD, Zeliadt SB, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fedorenko CR, Fairweather ME, Koepl LM, Thompson IM, Keane TE, **Penson DF**. Impact of Prostate Cancer on Sexual Relationships: A Longitudinal Perspective on Intimate Partners' Experiences. *J Sex Med*. 2013 Dec;10(12):3135-43. doi: 10.1111/jsm.12295. Epub 2013 Sep 30. PMID:2411898
22. Warren JL, Mariotto A, Melbert D, Schrag D, Doria-Rose P, **Penson D**, Yabroff KR. Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. *Med Care*. 2013 Dec 26. [Epub ahead of print] PMID:24374419
23. Barocas DA, Alvarez J, Koyama T, Anderson CB, Gray DT, Fowke JH, You C, Chang SS, Cookson MS, Smith JA Jr, **Penson DF**. Racial variation in the quality of surgical care for bladder cancer. *Cancer*. 2014 Apr 1;120(7):1018-25. doi: 10.1002/cncr.28520. Epub 2013 Dec 11. PMID:24339051
24. Bartsch G, Daneshmand S, Skinner EC, Syan S, Skinner DG, **Penson DF**. Urinary functional outcomes in female neobladder patients. *World J Urol*. 2014 Feb;32(1):221-8. doi: 10.1007/s00345-013-1219-8. Epub 2013 Dec 7. PMID:24317553
25. Barocas DA, Kulahalli CS, Ehrenfeld JM, Kapu AN, **Penson DF**, You CC, Weavind L, Dmochowski R. Benchmarking the use of a rapid response team by surgical services at a tertiary care hospital. *J Am Coll Surg*. 2014 Jan;218(1):66-72. doi: 10.1016/j.jamcollsurg.2013.09.011. Epub 2013 Nov 23. PMID:24275072
26. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup A, Wu XC, **Penson DF**. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. *J Comp Eff Res*. 2013 Jul;2(4):445-60. doi: 10.2217/ce.13.34. PMID:24236685
27. Tsai HT, **Penson DF**, Makambi KH, Lynch JH, Van Den Eeden SK, Potosky AL. Efficacy of intermittent androgen deprivation therapy vs conventional continuous

- androgen deprivation therapy for advanced prostate cancer: a meta-analysis. *Urology*. 2013 Aug;82(2):327-33. PMID:23896094
28. Krishnaswami S, Fannesbeck C, **Penson D**, McPheeters ML. Magnetic resonance imaging for locating nonpalpable undescended testicles: a meta-analysis. *Pediatrics*. 2013 Jun;131(6):e1908-16. Epub 2013 May 20. PMID:23690512
 29. **Penson D**, Krishnaswami S, Jules A, McPheeters ML. Effectiveness of hormonal and surgical therapies for cryptorchidism: a systematic review. *Pediatrics*. 2013 Jun;131(6):e1897-907. Epub 2013 May 20. PMID:23690511
 30. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, **Penson DF**, Kibel AS. Castration-resistant prostate cancer: AUA Guideline. *J Urol*. 2013 Aug;190(2):429-38. Epub 2013 May 9. PMID:23665272
 31. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, **Penson DF**, Zietman AL. Early detection of prostate cancer: AUA Guideline. *J Urol*. 2013 Aug;190(2):419-26. Epub 2013 May 6. PMID:23659877
 32. Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, Cookson MS, **Penson DF**, Davis R, Clark PE, Smith JA Jr, Chang SS. Incidence and Predictors of Understaging in Patients with Clinical T1 Urothelial Carcinoma Undergoing Radical Cystectomy. *BJU Int*. 2014 Jun;113(6):894-9. doi: 10.1111/bju.12245. Epub 2014 Apr 3. PMID:24053444
 33. Parikh AA, Ni S, Koyama T, Pawlik TM, **Penson D**. Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases: an Underutilized Strategy. *J Gastrointest Surg*. 2013 Nov;17(11):1938-46. doi: 10.1007/s11605-013-2325-z. Epub 2013 Sep 10 PMID:24018590
 34. Li C, Zeliadt SB, Hall IJ, Smith JL, Ekwueme DU, Moinpour CM, **Penson DF**, Thompson IM, Keane TE, Ramsey SD. Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. *Support Care Cancer*. 2013 Dec;21(12):3461-9. doi: 10.1007/s00520-013-1931-3. Epub 2013 Aug 17. PMID:23955026
 35. Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, **Penson DF**. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. *Urology*. 2013 Aug;82(2):410-5. PMID:23896100
 36. Daskivich, TJ, Fan KH, Koyama T, Albertson PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Litwin MS, **Penson DF**. Effect of Age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-

- based cohort of men with prostate cancer. *Ann Intern Med.*, 2013 May 21;158(10):709-17. PMID: 23689764.
37. Hoffman RM, Koyama T, Fan KH, Albertsen PC, Barry MJ, Goodman M, Hamilton AS, Potosky AL, Stanford JL, Stroup AM, **Penson DF**. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. *J Natl Cancer Inst.* 2013 May 15;105(10):711-8. Epub 2013 Apr 24. PMID: 23615689.
 38. Barocas, DA, Grubb R 3rd, **Penson DF**, Fowke JH, Andriole G, Crawford ED. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. *Cancer.* 2013 Jun 15;119(12):22223-9. Epub 2013 Apr 4. PMCID: 23559420.
 39. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, **Penson DF**. Long-term functional outcomes after treatment for localized prostate cancer. *N Engl J Med.* 2013 Jan 31;368(5):436-45. PMID: 23363497, PMCID: PMC3742365
 40. Etzioni R, Gulati R, Cooperberg MR, **Penson DF**, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. *Med Care.* 2013 Apr;51(4):295-300. PMID:23269114, PMCID:PMC3604989
 41. Anderson CB, Morgan TM, Kappa S, Moore D, Clark PE, Davis R, **Penson DF**, Barocas DA, Smith JA Jr, Cookson MS, Chang SS. Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? *J Urol.* 2013 Feb;189(2):541-7. Epub 2012 Dec 20. PMID: 23416635.
 42. Ahmadi H, Skinner EC, Simma-Chiang V, Miranda G, Cai J, **Penson DF**, Daneshmand. Urinary Functional Outcome Following Radical Cystoprostatectomy and Ileal Neobladder Reconstruction in Male Patients. *J Urol.* 2013 May;189(5):1782-8. Epub 2012 Nov 15. PMID: 23159582.
 43. Reynolds WS, Dmochowski RR, Lai J, Saigal C, **Penson DF**; Urologic Diseases in America Project. Patterns and Predictors of Urodynamics Use in the United States. *J Urol.* 2013 May;189(5):1791-6. doi: 10.1016/j.juro.2012.11.066. Epub 2012 Nov 15. PMID: 23159270.
 44. Anderson CB, **Penson DF**, Ni S, Makarov DV, Barocas DA. Centralization of Radical Prostatectomy in the United States. *J Urol.* 2013 Feb;189(2):500-6. Epub 2012 Oct 12. PMID: 23069384.

45. Reynolds WS, Gold KP, Ni S, Kaufman MR, Dmochowski RR, **Penson DF**. Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. *Neurourol Urodyn*. 2013 Apr;32(4):330-5. Epub 2012 Sep 21. PMID: 23001605.
46. Kaffenberger SD, Keegan KA, Bansal NK, Morgan TM, Tang DH, Barocas DA, **Penson DF**, Davis R, Clark PE, Chang SS, Cookson MS, Herrell SD, Smith JA Jr. Salvage Robotic-Assisted Laparoscopic Radical Prostatectomy: A Single Institution, Five-Year Experience. *J Urol*. 2013 Feb;189(2):507-13. Epub 2012 Sep 20. PMID: 23000849.
47. Kavitt RT, **Penson DF**, Vaezi MF. Eosinophilic esophagitis: dilate or medicate? A cost analysis model of the choice of initial therapy. *Dis Esophagus*. 2012 Sep 4. PMID: 22947137, NIHMSID: 479758.
48. Morgan TM, Barocas DA, Keegan KA, Cookson MS, Chang SS, Ni S, Clark PE, Smith JA Jr, **Penson DF**. Volume outcomes of cystectomy--is it the surgeon or the setting? *J Urol*. 2012 Dec;188(6):2139-44. PMID: 23083864
49. Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll PR, **Penson DF**. Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). *BJU Int*. 2012 Aug 29. PMID: PMC3540193.
50. Barocas DA, Gray DT, Fowke JH, Mercaldo ND, Blume JD, Chang SS, Cookson MS, Smith JA Jr, **Penson DF**. Racial variation in the quality of surgical care for prostate cancer. *J Urol*. 2012 Oct;188(4):1279-85. Epub 2012 Aug 16. PMID: 22902011.
51. Li C, Zeliadt SB, Hall IJ, Smith JL, Ekwueme DU, Moinpour CM, **Penson DF**, Thompson IM, Keane TE, Ramsey SD. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. *Value Health*. 2012 Jul-Aug;15(5):716-23. Epub 2012 Jun 7. PMID: 22867781.
52. Morgan TM, Barocas DA, **Penson DF**, Chang SS, Ni S, Clark PE, Smith JA Jr, Cookson MS. Lymph Node Yield at Radical Cystectomy Predicts Mortality in Node-negative and not Node-positive Patients. *Urology*. 2012 Sep;80(3):632-40. Epub 2012 Jul 13. PMID: 22795379.
53. Anderson CB, Feurer ID, Large MC, Steinberg GD, Barocas DA, Cookson MS, **Penson DF**. Psychometric Characteristics of a Condition-specific, Health-related Quality-of-life Survey: The FACT-Vanderbilt Cystectomy Index. *Urology*. 2012 Jul;80(1):77-83. Epub 2012 May 18, PMID:22608798.
54. Etzioni R, Gulati R, Tsodikov A, Wever EM, **Penson DF**, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB. The prostate cancer

- conundrum revisited: Treatment changes and prostate cancer mortality declines. *Cancer*. 2012 Dec 1;118(23):5955-63. doi: 10.1002/cncr.27594. Epub 2012 May 17 PMID:22605665, PMCID: PMC3424303.
55. Ramsey SD, Zeliadt SB, Blough DK, Fedorenko CR, Fairweather ME, McDermott CL, **Penson DF**, Van Den Eeden SK, Hamilton AS, Arora NK. Complementary and Alternative Medicine Use, Patient-reported Outcomes, and Treatment Satisfaction Among Men With Localized Prostate Cancer. *Urology*. 2012 May;79(5):1034-41. PMCID: PMC3489914.
 56. Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, **Penson DF**, Hachey M, Cynkin L, Carter GA, Campbell D, Percy-Laurry A, Zou Z, Schrag D, Hankey BF. The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. *Cancer*. 2012 Nov 15;118(22):5652-62. Epub 2012 May 8., PMID: 22569947.
 57. Klotz L, Chetner M, Chin J, Finelli T, Fleshner N, Fradet Y, Goldenberg L, Nickel JC, Siemens R, So A, Sugar L, Zlotta A, Klein E, Parnes H, **Penson D**. Canadian Consensus Conference: The FDA decision on the use of 5ARIs. *Can Urol Assoc J*. 2012 Apr;6(2):83-8. PMCID:PMC3328559.
 58. Makarov DV, Desai R, Yu JB, Sharma R, Abraham N, Albertsen PC, Krumholz HM, **Penson DF**, Gross CP. Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat. *Health Aff (Millwood)*. 2012 Apr;31(4):730-40. PMID: 22492890.
 59. Dageforde LA, Moore DR, Landman MP, Feurer ID, Pinson CW, Poulouse B, **Penson DF**, Moore DE. Comparison of open live donor nephrectomy, laparoscopic live donor nephrectomy, and hand-assisted live donor nephrectomy: A cost-minimization analysis. *J Surg Res*. 2012 Aug;176(2):e89-94 PMID: 22472697.
 60. Patel SG, **Penson DF**, Pabla B, Clark PE, Cookson MS, Chang SS, Herrell SD, Smith JA Jr, Barocas DA. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. *J Urol*. 2012 Mar;187(3):816-21. PMID: 22248514.
 61. Fowke JH, Motley SS, Concepcion RS, **Penson DF**, Barocas DA. Obesity, body composition, and prostate cancer. *BMC Cancer*. 2012 Jan 18;12:23. PMID:. PMCID: PMC3292483.
 62. Makarov DV, Desai RA, Yu JB, Sharma R, Abraham N, Albertsen PC, **Penson DF**, Gross CP. The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare

- population. *J Urol*. 2012 Jan;187(1):97-102. Epub 2011 Nov 16. PMID: 22088337.
63. **Penson DF**, Munro HM, Signorello LB, Blot WJ, Fowke JH; Urologic Diseases in America Project. Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. *J Urol*. 2011 Dec;186(6):2316-22. Epub 2011 Oct 20. PMID: PMC3327364.
 64. Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, **Penson DF**, Smith JA Jr, Barocas DA. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. *J Urol*. 2011 Dec;186(6):2221-7. Epub 2011 Oct 19. PMID: 22014803.
 65. Fowke JH, Munro H, Signorello LB, Blot WJ, **Penson DF**; Urologic Diseases of America Project. Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. *J Gen Intern Med*. 2011 Nov;26(11):1305-10. Epub 2011 Jul 1. PMID: 21720905; PMID: PMC3208454.
 66. Poulouse BK, Phillips S, Nealon W, Shelton J, Kummerow K, **Penson D**, Holzman MD. Choledocholithiasis management in rural America: health disparity or health opportunity? *J Surg Res*. 2011 Oct;170(2):214-9. Epub 2011 Apr 15. PMID: 21571311.
 67. Poulouse BK, Shelton J, Phillips S, Moore D, Nealon W, **Penson D**, Beck W, Holzman MD. Epidemiology and cost of ventral hernia repair: making the case for hernia research. *Hernia*. 2012 Apr;16(2):179-83. Epub 2011 Sep 9. PMID: 21904861.
 68. Morgan TM, Barocas DA, Chang SS, Phillips SE, Salem S, Clark PE, **Penson DF**, Smith JA Jr, Cookson MS. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. *Urol Oncol*. 2013 Aug;31(6):871-7. Epub 2011 Sep 9. PMID: PMC3253245.
 69. Zeliadt SB, **Penson DF**, Moinpour CM, Blough DK, Fedorenko CR, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. *BJU Int*. 2011 Sep;108(6):851-6; Epub 2011 Jan 18. PMID: 21244609.
 70. Birkhahn M, **Penson DF**, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG, Cote RJ. Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. *BJU Int*. 2011 Sep;108(5):660-4. Epub 2011 Jan 12. PMID: 21223479.

71. Morgan TM, Keegan KA, Barocas DA, Ruhotina N, Phillips SE, Chang SS, **Penson DF**, Clark PE, Smith JA Jr, Cookson MS. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. *J Urol*. 2011 Sep;186(3):829-34. Epub 2011 Jul 23. PMID: 21788035.
72. Barocas DA, Motley S, Cookson MS, Chang SS, **Penson DF**, Dai Q, Milne G, Roberts LJ 2nd, Morrow J, Concepcion RS, Smith JA Jr, Fowke JH. Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. *J Urol*. 2011 Jun;185(6):2102-7. Epub 2011 Apr 15. PMCID: PMC3093434.
73. Gulati R, Wever EM, Tsodikov A, **Penson DF**, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R. What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. *Cancer Epidemiol Biomarkers Prev*. 2011 May;20(5):740-50. PMCID: PMC3091266.
74. Wessells H, **Penson DF**, Cleary P, Rutledge BN, Lachin JM, McVary KT, Schade DS, Sarma AV; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. *J Urol*. 2011 May;185(5):1828-34. Epub 2011 Mar 21. PMCID: PMC3220602.
75. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, **Penson DF**, Ulchaker JC, Wei JT. Update on AUA guideline on the management of benign prostatic hyperplasia. *J Urol*. 2011 May;185(5):1793-803. Epub 2011 Mar 21. PMID:21420124.
76. Thong MS, van de Poll-Franse L, Hoffman RM, Albertsen PC, Hamilton AS, Stanford JL, **Penson DF**. Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. *BJU Int*. 2011 Apr;107(8):1223-31. Epub 2010 Nov 11. PMCID: PMC3292346.
77. Makarov DV, Yu JB, Desai RA, **Penson DF**, Gross CP. The association between diffusion of the surgical robot and radical prostatectomy rates. *Med Care*. 2011 Apr;49(4):333-9. PMID: 21368677.
78. Hamilton AS, Albertsen PC, Johnson TK, Hoffman R, Morrell D, Deapen D, **Penson DF**. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. *BJU Int*. 2011 Feb;107(4):576-84. Epub 2010 Aug 24. PMID: 20735387.
79. Epplein M, Zheng Y, Zheng W, Chen Z, Gu K, **Penson D**, Lu W, Shu XO. Quality of life after breast cancer diagnosis and survival. *J Clin Oncol*. 2011 Feb 1;29(4):406-12. Epub 2010 Dec 20. PMCID: PMC3058286.

80. Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, **Penson DF**. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. *World J Urol*. 2011 Feb;29(1):51-7. Epub 2010 Nov 26. PMID: 21110030.
81. Ramsey SD, Zeliadt SB, Fedorenko CR, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fairweather ME, Thompson IM, Keane TE, **Penson DF**. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. *World J Urol*. 2011 Feb;29(1):3-9. Epub 2010 Oct 20. PMID: 20959991.
82. Maripuri S, **Penson DF**, Ikizler TA, Cavanaugh KL. Outpatient versus inpatient observation after percutaneous native kidney biopsy: a cost minimization study. *Am J Nephrol*. 2011;34(1):64-70. Epub 2011 Jun 14. PMCID: PMC3123742.
83. Rim SH, Hall IJ, Fairweather ME, Fedorenko CR, Ekwueme DU, Smith JL, Thompson IM, Keane TE, **Penson DF**, Moinpour CM, Zeliadt SB, Ramsey SD. Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. *Int J Gen Med*. 2011;4:481-6. Epub 2011 Jun 17. PMCID: PMC3133516.
84. Hadley J, Yabroff KR, Barrett MJ, **Penson DF**, Saigal CS, Potosky AL. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. *J Natl Cancer Inst*. 2010 Dec 1;102(23):1780-93. Epub 2010 Oct 13. PMCID: PMC2994860.
85. Stimson CJ, Dmochowski R, **Penson DF**. Health care reform 2010: a fresh view on tort reform. *J Urol*. 2010 Nov;184(5):1840-6. Epub 2010 Sep 17. PMID: 20846694.
86. Zeliadt SB, Ramsey SD, Van Den Eeden SK, Hamilton AS, Oakley-Girvan I, **Penson DF**, Fairweather ME, Arora NK, Potosky AL. Patient recruitment methods to evaluate treatment decision making for localized prostate cancer. *Am J Clin Oncol*. 2010 Aug;33(4):381-6. PMID: 20010079.
87. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, **Penson DF**, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*. 2010 Jul 29;363(5):411-22. PMID: 20818862.
88. Ramsey SD, Zeliadt SB, Arora NK, Blough DK, **Penson DF**, Oakley-Girvan I, Hamilton AS, Van Den Eeden SK, Fedorenko CR, Potosky AL. Unanticipated and underappreciated outcomes during management of local stage prostate

- cancer: a prospective survey. *J Urol.* 2010 Jul;184(1):120-5. Epub 2010 May 15. PMID: 20478590.
89. Huang GJ, Sadetsky N, **Penson DF**. Health related quality of life for men treated for localized prostate cancer with long-term followup. *J Urol.* 2010 Jun;183(6):2206-12. PMID: 20399462.
 90. Zeliadt SB, Moinpour CM, Blough DK, **Penson DF**, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Preliminary treatment considerations among men with newly diagnosed prostate cancer. *Am J Manag Care.* 2010 May 1;16(5):e121-30. PMID: 20455638.
 91. Makarov DV, Loeb S, Landman AB, Nielsen ME, Gross CP, Leslie DL, **Penson DF**, Desai RA. Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. *J Urol.* 2010 Apr;183(4):1504-9. Epub 2010 Feb 20. PMID: 20172559.
 92. Moses KA, Paciorek AT, **Penson DF**, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. *J Clin Oncol.* 2010 Feb 20;28(6):1069-74. Epub 2010 Jan 25. PMCID: PMC2834431.
 93. Bruins HM, Huang GJ, Cai J, Skinner DG, Stein JP, **Penson DF**. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. *J Urol.* 2009 Nov;182(5):2182-7. Epub 2009 Sep 15. PMID:19758623.
 94. Osswald M, Harlan LC, **Penson D**, Stevens JL, Clegg LX. Treatment of a population based sample of men diagnosed with testicular cancer in the United States. *Urol Oncol.* 2009 Nov-Dec;27(6):604-10. Epub 2008 Sep 16. PMCID: PMC2782764.
 95. Ramsey SD, Zeliadt SB, Arora NK, Potosky AL, Blough DK, Hamilton AS, Van Den Eeden SK, Oakley-Girvan I, **Penson DF**. Access to information sources and treatment considerations among men with local stage prostate cancer. *Urology.* 2009 Sep;74(3):509-15. Epub 2009 Jul 9. PMCID: PMC2748115.
 96. Bergman J, Gore JL, **Penson DF**, Kwan L, Litwin MS. Erectile aid use by men treated for localized prostate cancer. *J Urol.* 2009 Aug;182(2):649-54. Epub 2009 Jun 17. PMID: 19535108.
 97. **Penson DF**, Wessells H, Cleary P, Rutledge BN; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. *J Sex Med.* 2009 Jul;6(7):1969-78. Epub 2009 Apr 28. PMCID: PMC2861494.

98. Nichol MB, Knight TK, Wu J, Barron R, **Penson DF**. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. *J Urol*. 2009 May;181(5):2214-21; Epub 2009 Mar 17. PMID: 19296986.
99. Stein JP, **Penson DF**, Lee C, Cai J, Miranda G, Skinner DG. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. *J Urol*. 2009 May;181(5):2052-8; Epub 2009 Mar 14. PMID: 19286213.
100. **Penson DF**, Rossignol M, Sartor AO, Scardino PT, Abenhaim LL. Prostate cancer: epidemiology and health-related quality of life. *Urology*. 2008 Dec;72(6 Suppl):S3-11. PMID: 19095126.
101. Sartor AO, Hricak H, Wheeler TM, Coleman J, **Penson DF**, Carroll PR, Rubin MA, Scardino PT. Evaluating localized prostate cancer and identifying candidates for focal therapy. *Urology*. 2008 Dec;72(6 Suppl):S12-24. PMID: 19095124.
102. Neuhaus ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, **Penson DF**, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. *Prostate*. 2008 Sep 15;68(13):1477-86. PMID: 182564287.
103. Huang GJ, Hamilton AS, Lo M, Stein JP, **Penson DF**. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. *J Urol*. 2008 Aug;180(2):520-4; Epub 2008 Jun 11. PMID: 183327445.
104. Zeliadt SB, Ramsey SD, Potosky AL, Arora NK, Blough DK, Oakley-Girvan I, Hamilton AS, Van Den Eeden SK, **Penson DF**. Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. *Patient*. 2008 Jul 1;1(3):189. PMID: 182812903.
105. **Penson DF**, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. *J Urol*. 2008 May;179(5 Suppl):S40-4. PMID: 18405749.
106. Etzioni R, Gulati R, Falcon S, **Penson DF**. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. *Med Decis Making*. 2008 May-Jun;28(3):323-31. Epub 2008 Mar 4. PMID: 18319508.
107. Kristal AR, Arnold KB, Schenk JM, Neuhaus ML, Goodman P, **Penson DF**, Thompson IM. Dietary patterns, supplement use, and the risk of symptomatic

- benign prostatic hyperplasia: results from the prostate cancer prevention trial. *Am J Epidemiol.* 2008 Apr 15;167(8):925-34. Epub 2008 Feb 7. PMID: 18263602.
108. Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, **Penson DF**, Feuer E. Quantifying the role of PSA screening in the US prostate cancer mortality decline. *Cancer Causes Control.* 2008 Mar;19(2):175-81. Epub 2007 Nov 20. PMID: PMC3064270.
 109. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, **Penson DF**, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. *Clin Cancer Res.* 2008 Jan 1;14(1):224-9. PMID: 18172274.
 110. Lloyd A, **Penson D**, Dewilde S, Kleinman L. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. *Prostate Cancer Prostatic Dis.* 2008;11(2):153-9. Epub 2007 Jul 17. PMID: 17637761.
 111. **Penson DF**, Chan JM; Urologic Diseases in America Project. Prostate cancer. *J Urol.* 2007 Jun;177(6):2020-9. PMID: 17509282.
 112. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, Antvelink CM, **Penson DF**, Thompson IM. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. *J Urol.* 2007 Apr;177(4):1395-400; PMID: 17382740.
 113. Graff JN, Mori M, Li H, Garzotto M, **Penson D**, Potosky AL, Beer TM. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. *J Urol.* 2007 Apr;177(4):1307-12. PMID: 17382720.
 114. Albertsen PC, Hanley JA, **Penson DF**, Barrows G, Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. *J Urol.* 2007 Mar;177(3):932-6. PMID: 17296379.
 115. Stein JP, **Penson DF**, Cai J, Miranda G, Skinner EC, Dunn MA, Groshen S, Lieskovsky G, Skinner DG. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. *J Urol.* 2007 Mar;177(3):876-81; PMID: 17296365.
 116. Zeliadt SB, Etzioni R, Ramsey SD, **Penson DF**, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. *Med Care.* 2007 Feb;45(2):154-9. PMID: 17224778.

117. Latini DM, Chan JM, Cowan JE, Arredondo SA, Kane CJ, **Penson DF**, DuChane J, Carroll PR; CaPSURE Investigators. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. *Urology*. 2006 Dec;68(6):1242-7. Epub 2006 Dec 4. PMID: 17141841.
118. Latini DM, **Penson DF**, Wallace KL, Lubeck DP, Lue TF. Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED. *J Sex Med*. 2006 Nov;3(6):1068-76. PMID: 17100940.
119. Latini DM, **Penson DF**, Wallace KL, Lubeck DP, Lue TF. Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED. *J Sex Med*. 2006 Nov;3(6):1059-67. PMID: 17100939.
120. Sanderson KM, **Penson DF**, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. *J Urol*. 2006 Nov;176(5):2025-31;. PMID: 17070244.
121. Zeliadt SB, Potosky AL, **Penson DF**, Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. *Int J Radiat Oncol Biol Phys*. 2006 Oct 1;66(2):395-402. Epub 2006 Aug 14. PMID: 16904843.
122. Gore JL, **Penson DF**, Litwin MS. Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer. *Nat Clin Pract Urol*. 2006 Aug;3(8):449-52. PMID: 16902521.
123. Yang CC, Porter MP, **Penson DF**. Comparison of the International Index of Erectile Function erectile domain scores and nocturnal penile tumescence and rigidity measurements: does one predict the other? *BJU Int*. 2006 Jul;98(1): PMID: 16831153.
124. **Penson D**, Moul J, Gandhi S, Newling D. Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists. *Urology*. 2006 Jul;68(1):80-4. Epub 2006 Jun 13. PMID: 16777198.
125. Zeliadt SB, Ramsey SD, **Penson DF**, Hall IJ, Ekwueme DU, Stroud L, Lee JW. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. *Cancer*. 2006 May 1;106(9):1865-74. PMID: 16568450.
126. Black PC, **Penson DF**. Prostate cancer on the Internet--information or misinformation? *J Urol*. 2006 May;175(5):1836-42; PMID: 16600774.

127. Concato J, Wells CK, Horwitz RI, **Penson D**, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P. The effectiveness of screening for prostate cancer: a nested case-control study. *Arch Intern Med*. 2006 Jan 9;166(1):38-43. PMID: 16401808.
128. Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, **Penson D**. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? *Urology*. 2005 Oct;66(4):835-9. PMID:16230148.
129. Albertsen PC, Hanley JA, Barrows GH, **Penson DF**, Kowalczyk PD, Sanders MM, Fine J. Prostate cancer and the Will Rogers phenomenon. *J Natl Cancer Inst*. 2005 Sep 7;97(17):1248-53. PMID: 16145045.
130. Etzioni RD, Howlader N, Shaw PA, Ankerst DP, **Penson DF**, Goodman PJ, Thompson IM. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. *J Urol*. 2005 Sep;174(3):877-81. PMID: 16093979.
131. Zeliadt SB, Etzioni RD, **Penson DF**, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. *Am J Med*. 2005 Aug;118(8):850-7. PMID: 16084177.
132. **Penson DF**, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. *J Urol*. 2005 Aug;174(2):547-52; discussion 552. PMID: 16006889.
133. **Penson DF**, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. *J Urol*. 2005 May;173(5):1701-5. PMID: 15821561.
134. Porter MP, **Penson DF**. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. *J Urol*. 2005 Apr;173(4):1318-22. PMID: 15758789.
135. Paick SH, Meehan A, Lee M, **Penson DF**, Wessells H. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. *J Urol*. 2005 Mar;173(3):903-7. PMID: 15711315.
136. Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, **Penson DF**, Weiss NS, Feuer EJ. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. *Am J Epidemiol*. 2004 Dec 1;160(11):1059-69. PMID: 15561985.

137. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, **Penson DF**. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. *Urology*. 2004 Dec;64(6):1171-6. PMID: 15596192.
138. Hoffman RM, Gilliland FD, **Penson DF**, Stone SN, Hunt WC, Potosky AL. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. *Cancer*. 2004 Nov 1;101(9):2011-9. PMID: 15452835.
139. Rosenfeld B, Roth AJ, Gandhi S, **Penson D**. Differences in health-related quality of life of prostate cancer patients based on stage of cancer. *Psychooncology*. 2004 Nov;13(11):800-7. PMID: 15386638.
140. Johnson TK, Gilliland FD, Hoffman RM, Deapen D, **Penson DF**, Stanford JL, Albertsen PC, Hamilton AS. Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. *J Clin Oncol*. 2004 Oct 15;22(20):4193-201. PMID: 15483030.
141. Etzioni R, Falcon S, Gann PH, Kooperberg CL, **Penson DF**, Stampfer MJ. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? *Cancer Epidemiol Biomarkers Prev*. 2004 Oct;13(10):1640-5. PMID: 15466981.
142. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, **Penson DF**, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. *J Natl Cancer Inst*. 2004 Sep 15;96(18):1358-67. PMID: 15367568.
143. Neuhauser ML, Kristal AR, **Penson DF**. Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. *Urology*. 2004 Aug;64(2):201-11. PMID: 15302461.
144. Inoue LY, Etzioni R, Slate EH, Morrell C, **Penson DF**. Combining longitudinal studies of PSA. *Biostatistics*. 2004 Jul;5(3):483-500. PMID: 15208207.
145. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. *J Urol*. 2004 Jun;171(6 Pt 1):2250-4. PMID: 15126796.
146. Albertsen PC, Hanley JA, **Penson DF**, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized

- prostate cancer with surgery or radiation. *J Urol*. 2004 Jun;171(6 Pt 1):2221-5. PMID: 15126789.
147. Cooperberg MR, Lubeck DP, **Penson DF**, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. *J Urol*. 2003 Sep;170(3):905-8. PMID: 12913727.
 148. Zeliadt SB, **Penson DF**, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. *Cancer*. 2003 Aug 1;98(3):496-503. PMID: 12879465.
 149. Plaskon LA, **Penson DF**, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. *Cancer Epidemiol Biomarkers Prev*. 2003 Jul;12(7):604-9. PMID: 12869398.
 150. **Penson DF**, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. *J Urol*. 2003 May;169(5):1653-61. PMID: 12686803.
 151. **Penson DF**, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF; Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. *Diabetes Care*. 2003 Apr;26(4):1093-9. PMID: 12663579.
 152. **Penson DF**, Latini DM, Lubeck DP, Wallace K, Henning JM, Lue T. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. *J Urol*. 2003 Apr;169(4):1458-61. PMID: 12629383.
 153. Latini DM, **Penson DF**, Lubeck DP, Wallace KL, Henning JM, Lue TF. Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. *J Urol*. 2003 Apr;169(4):1437-42. PMID: 12629379.
 154. **Penson DF**, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. *J Clin Oncol*. 2003 Mar 15;21(6):1147-54. PMID: 12637483.
 155. **Penson DF**, Paltiel AD, Krumholz HM, Palter S. The cost-effectiveness of treatment for varicocele related infertility. *J Urol*. 2002 Dec;168(6):2490-4. PMID: 12441947.

156. Krieger JN, Ross SO, **Penson DF**, Riley DE. Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. *Urology*. 2002 Dec;60(6):959-63. PMID: 12475649.
157. Latini DM, **Penson DF**, Colwell HH, Lubeck DP, Mehta SS, Henning JM, Lue TF. Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. *J Urol*. 2002 Nov;168(5):2086-91. PMID: 12394715.
158. Porter MP, Voigt LF, **Penson DF**, Weiss NS. Racial variation in the incidence of squamous cell carcinoma of the bladder in the United States. *J Urol*. 2002 Nov;168(5):1960-3. PMID: 12394685.
159. Etzioni R, **Penson DF**, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. *J Natl Cancer Inst*. 2002 Jul 3;94(13):981-90. PMID: 12096083.
160. **Penson DF**, Grossfeld GD, Li YP, Henning JM, Lubeck DP, Carroll PR. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. *J Urol*. 2002 Apr;167(4):1653-7; PMID: 11912382.
161. Billingsley KG, Schwartz DL, Lentz S, Vallières E, Montgomery RB, Schubach W, **Penson D**, Yueh B, Chansky H, Zink C, Parayno D, Starkebaum G. The development of a telemedical cancer center within the Veterans Affairs Health Care System: a report of preliminary clinical results. *Telemed J E Health*. 2002 Spring;8(1):123-30. PMID: 12020412.
162. **Penson DF**, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? *J Natl Cancer Inst*. 2001 Dec 5;93(23):1822-3. PMID: 11734600.
163. Lubeck DP, Kim H, Grossfeld G, Ray P, **Penson DF**, Flanders SC, Carroll PR. Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor. *J Urol*. 2001 Dec;166(6):2281-5. PMID: 11696752.
164. **Penson DF**. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. *Rev Urol*. 2001 Summer;3(3):113-9. PMID: PMC1557409.
165. **Penson DF**, Stoddard ML, Pasta DJ, Lubeck DP, Flanders SC, Litwin MS. The association between socioeconomic status, health insurance coverage, and quality

- of life in men with prostate cancer. *J Clin Epidemiol*. 2001 Apr;54(4):350-8. PMID: 11297885.
166. **Penson DF**, Schonfeld WH, Flanders SC, Henke CJ, Warolin KL, Carroll PR, Litwin MS. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. *Urology*. 2001 Mar;57(3):499-503. PMID: 11248628.
 167. Corman JM, **Penson DF**, Hur K, Khuri SF, Daley J, Henderson W, Krieger JN. Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. *BJU Int*. 2000 Nov;86(7):782-9. PMID: 11069401.
 168. Anderson DR, Patil S, Kamina A, **Penson DF**, Peduzzi P, Concato J. Validation of a staging system for evaluating prognosis in prostate cancer. *Conn Med*. 2000 Aug;64(8):459-64. PMID: 10984970.
 169. Taneja SS, **Penson DF**, Epelbaum A, Handler T, Lepor H. Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen. *J Urol*. 1999 Oct;162(4):1352-7; discussion 1357-8. PMID: 10492195.
 170. Litwin MS, **Penson DF**. Health-related quality of life in men with prostate cancer. *Prostate Cancer Prostatic Dis*. 1998 Sep;1(5):228-235. PMID: 12496881.
 171. **Penson DF**, Litwin MS, Lubeck DP, Flanders S, Pasta DJ, Carroll PR. Transitions in health-related quality of life during the first nine months after diagnosis with prostate cancer. *Prostate Cancer Prostatic Dis*. 1998 Mar;1(3):134-143. PMID: 12496906.
 172. **Penson DF**, Lugg JA, Coyne C, Sadeghi F, Freedman AL, Gonzalez-Cadavid NF, Rajfer J. Effect of cryptorchidism on testicular histology in a naturally cryptorchid animal model. *J Urol*. 1997 Nov;158(5):1978-82. PMID: 9334653.
 173. **Penson DF**, Ng C, Rajfer J, Gonzalez-Cadavid NF. Adrenal control of erectile function and nitric oxide synthase in the rat penis. *Endocrinology*. 1997 Sep;138(9):3925-32. PMID: 9275083.
 174. Marks LS, **Penson DF**, Maller JJ, Nielsen RT, deKernion JB. Computer-generated graphical presentations: use of multimedia to enhance communication. *Urology*. 1997 Jan;49(1):2-9. PMID: 9000177.
 175. Lugg JA, **Penson DF**, Sadeghi F, Petrie B, Freedman AL, Gonzalez-Cadavid NF, Hikim AS, Rajfer J. Prevention of seminiferous tubular atrophy in a naturally cryptorchid rat model by early surgical intervention. *J Androl*. 1996 Nov-Dec;17(6):726-32. PMID: 9016404.

176. **Penson DF**, Ng C, Cai L, Rajfer J, González-Cadavid NF. Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. *Biol Reprod.* 1996 Sep;55(3):567-74. PMID: 8862773.
177. **Penson DF**, Aronson WJ. Segmental testicular infarction in the neonate: a case report. *J Urol.* 1995 Jun;153(6):1992-3. PMID: 7752381.
178. **Penson DF**, Seftel AD, Krane RJ, Frohrib D, Goldstein I. The hemodynamic pathophysiology of impotence following blunt trauma to the erect penis. *J Urol.* 1992 Oct;148(4):1171-80. PMID: 1404631.

Review Articles

179. Hautmann RE, Abol-Enein H, Lee CT, Mansson W, Mills RD, **Penson DF**, Skinner EC, Studer UE, Thueroff JW, Volkmer BG. Urinary diversion: how experts divert. *Urology.* 2015 Jan;85(1):233-8. doi:10.1016/j.urology.2014.06.075. Epub 2014 Nov 8. PMID: 25440985
180. Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, **Penson DF**, Rosario DJ, Tombal B, Smith MR. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. *Eur Urol.* 2014 Aug 2. pii: S0302-2838(14)00650-2. doi: 10.1016/j.eururo.2014.07.010. [Epub ahead of print] PMID: 25097095
181. Kaffenberger SD, **Penson DF**. The politics of prostate cancer screening. *Urol Clin North Am.* 2014 May;41(2):249-55. doi: 10.1016/j.ucl.2014.01.004. Epub 2014 Feb 19. PMID: 24725487
182. Hoffman RM, **Penson DF**, Zietman AL, Barry MJ. Comparative effectiveness research in localized prostate cancer treatment. *J Comp Eff Res.* 2013 Nov;2(6):583-93. doi: 10.2217/cer.13.66. PMID:24236797
183. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, **Penson DF**, Carter HB, Carroll P, Etzioni R. Overdiagnosis and Overtreatment of Prostate Cancer. *Eur Urol.* 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9. PMID:24439788
184. Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, Wheeler TM, Schlossberg S, **Penson DF**, Taneja SS. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. *J Urol.* 2013 Jun;189(6):2039-46. Epub 2013 Feb 26. PMID:23485507
185. Keegan KA, **Penson DF**. The patient protection and affordable care act: The impact on urologic cancer care. *Urol Oncol.* 2013 Oct;31(7):980-4. PMID: 22819697

186. Resnick, MJ **Penson, DF**. Quality of life with advanced metastatic prostate cancer. *Urol Clin North Am*. 2012 Nov;39(4):505-15. PMID: 23084527
187. Klotz L, Chetner M, Chin J, Finelli T, Fleshner N, Fradet Y, Goldenberg L, Nickel JC, Siemens R, So A, Sugar L, Zlotta A, Klein E, Parnes H, **Penson D**. Canadian Consensus Conference: The FDA decision on the use of 5ARIs. *Can Urol Assoc J*. 2012 Apr;6(2):83-8. PMCID: PMC3328559
188. Reynolds WS, Dmochowski RR, **Penson DF**. Epidemiology of stress urinary incontinence in women. *Curr Urol Rep*. 2011 Oct;12(5):370-6. PMID: 21720817.
189. Gomelsky A, **Penson DF**, Dmochowski RR. Pelvic organ prolapse (POP) surgery: the evidence for the repairs. *BJU Int*. 2011 Jun;107(11):1704-19. PMID: 21592280.
190. Barocas DA, **Penson DF**. Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. *BJU Int*. 2010 Aug;106(3):322-8. Epub 2010 Jun 14. PMCID: PMC2910169.
191. Miller, E and **Penson, D.F.**, Lies, Damn Lies and Statistics: A Clinician's Primer. *AUA Update Series* 28(33): 306-311, 2009.
192. **Penson DF**: Active surveillance: not your father's watchful waiting. *Oncology (Williston Park)*. 2009 Oct;23(11):980, 982. PMID: 19947350
193. **Penson, D.F.**: Assessing the quality of prostate cancer care. *Curr Opin Urol*. 2008 May;18(3):297-302. PMID: 18382239
194. Stein JP, Hautmann RE, **Penson D**, Skinner DG. Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. *Urol Oncol*. 2009 Sep-Oct;27(5):466-72. Epub 2008 Oct 10. Review. PMID: 18848788.
195. Makarov DV, **Penson DF**. Prostate cancer: quality of life after radiation and androgen deprivation. *Nat Rev Urol*. 2009 Sep;6(9):477-8. PMID: 19727147.
196. Gonzalez CM, **Penson D**, Kosiak B, Dupree J, Clemens JQ. Pay for performance: rationale and potential implications for urology. *J Urol*. 2007 Aug;178(2):402-8. Epub 2007 Jun 11. PMID: 17561159.
197. Stein JP, **Penson DF**, Wu SD, Skinner DG. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. *J Urol*. 2007 Sep;178(3 Pt 1):756-60. Epub 2007 Jul 13. PMID: 17631333.

198. Stein JP, **Penson DF**: The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy. *Curr Urol Rep*. 2008 May;9(3):179-81. PMID: 18765110.
199. Stein, JP, **Penson, DF**: Invasive T1 bladder cancer: indications and rationale for radical cystectomy. *BJU Int*. 2008 Aug;102(3):270-5. Epub 2008 May 20. PMID: PMID:18494831.
200. Huang GJ, **Penson DF**. Internet health resources and the cancer patient. *Cancer Invest*. 2008 Mar;26(2):202-7. PMID: 18259953.
201. Zeliadt SB, **Penson DF**. Pharmacoeconomics of available treatment options for metastatic prostate cancer. *Pharmacoeconomics*. 2007;25(4):309-27. PMID: 17402804.
202. Ramsey SD, Zeliadt SB, Hall IJ, Ekwueme DU, **Penson DF**. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. *J Urol*. 2007 Jun;177(6):1992-9. PMID: 17509278.
203. **Penson DF**. Quality of life after therapy for localized prostate cancer. *Cancer J*. 2007 Sep-Oct;13(5):318-26. PMID: 17921731.
204. Dall’Era MA, **Penson DF**: Assessing Outcomes in Urology: Part I Urologic Oncology. *AUA Update Series*, Vol. 25, lesson 26, pp 237-244, 2006.
205. **Penson DF**: Assessing Outcomes in Urology: Part II Benign Urologic Conditions. *AUA Update Series*, Vol. 25, lesson 27, pp 245-252, 2006.
206. **Penson DF**. An update on randomized clinical trials in localized and locoregional prostate cancer. *Urol Oncol*. 2005 Jul-Aug;23(4):280-8. PMID: 16018945.
207. Quek ML, **Penson DF**. Quality of life in patients with localized prostate cancer. *Urol Oncol*. 2005 May-Jun;23(3):208-15. PMID: 15907723.
208. Porter MP, Wei JT, **Penson DF**. Quality of life issues in bladder cancer patients following cystectomy and urinary diversion. *Urol Clin North Am*. 2005 May; 32(2):207-16. PMID: 15862618.
209. **Penson, DF**, Wessells, H: Erectile Dysfunction in Diabetic Patients. *Diabetes Spectrum*, 2004, 17(4): 225-232.
210. **Penson DF**, Litwin MS. The physical burden of prostate cancer. *Urol Clin North Am*. 2003 May;30(2):305-13. PMID: 12735506.
211. **Penson DF**, Litwin MS. Quality of life after treatment for prostate cancer. *Curr Urol Rep*. 2003 Jun;4(3):185-95. PMID: 12756081.

212. Moul JW, Anderson J, **Penson DF**, Klotz LH, Soloway MS, Schulman CC. Early prostate cancer: prevention, treatment modalities, and quality of life issues. *Eur Urol*. 2003 Sep;44(3):283-93. PMID: 12932925.
213. **Penson DF**, Albertsen PC. Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom. *Surg Oncol*. 2002 Jun;11(1-2):3-11. PMID: 12031863.
214. Lee R, **Penson DF**. Treatment outcomes in localized prostate cancer: a patient-oriented approach. *Semin Urol Oncol*. 2002 Feb;20(1):63-73. PMID: 11828359.
215. **Penson, DF**, Litwin MS, Quality of life issues in men with prostate cancer. *AUA Update Series*, 2001, 20(3): 18-2.
216. **Penson, DF**, Urinary dysfunction and quality of life in patients with prostate cancer. *Primary Care and Cancer*, 2000, 20(8): 47-51.
217. **Penson DF**. Quality of life following prostate cancer treatments. *Curr Urol Rep*. 2000 May;1(1):71-7. PMID: 12084344.
218. **Penson DF**, Litwin MS. Quality of Life after Treatment for Localized Prostate Cancer. *Contemporary Urology*, 2000, 12(2): 35-43.
219. **Penson DF**, Litwin MS. Quality of Life after Treatment for Prostate Cancer. *Urology News*, 1999, 3(4): 6-8.
220. **Penson DF**, Litwin MS. Health-related Quality of Life and Genitourinary Malignancies. *AUA Update Series*, 1997, 16(5): 34-39.
221. **Penson DF**, Litwin MS. Quality of Life Assessment in Urology. *Contemporary Urology*, 1997, 9(3): 53-66.

Scientific Reports

222. Hautmann RE, Abol-Enein H, Davidsson T, Gudjonsson S, Hautmann SH, Holm HV, Lee CT, Liedberg F, Madersbacher S, Manoharan M, Mansson W, Mills RD, **Penson DF**, Skinner EC, Stein R, Studer UE, Thueroff JW, Turner WH, Volkmer BG, Xu A. ICUD-EAU International Consultation on Bladder Cancer 2012: urinary diversion. *Eur Urol*. 2013 Jan;63(1):67-80. PMID: 22995974.
223. **Penson DF**, Krishnaswami S, Jules A, Seroogy JC, McPheeters ML. Evaluation and Treatment of Cryptorchidism. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Dec. Report No.: 13-EHC001-EF.
224. **Penson DF**, Barocas DA, Fleshner N, Sanda MG, Greenfield S. Outcomes Session. *Urol Oncol*. 2012 Nov-Dec;30(6):952-5. PMID: 23218075.

225. McKoy JN, Hartmann KE, Jerome RN, Andrews JC, **Penson DF**. Future Research Needs for Outcomes of Weight Gain in Pregnancy. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Nov. Report No.: 11-EHC004-EF.
226. **Penson, DF**, Chan, JM. Prostate Cancer. In: Litwin, M.S., Saigal, C.S., editors. Urologic Diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Diabetes, Digestive and Kidney Diseases. Washington DC: US Government Publishing Office, 2007, NIH Publication no. 07-5512, pp.71-122.
227. **Penson, DF**, Sokoloff, MH. Management of Side Effects of Prostate Cancer Therapy. In “Report to the Nation on Prostate Cancer”. The Prostate Cancer Foundation, Medscape, 2004. <http://www.medscape.com/viewprogram/3446>

NON-PEER REVIEWED

Selected Invited Editorials

1. **Penson, DF**. The hidden agenda in the release of the Medicare physician reimbursement data. Urology. 2014 Sep;84(3):501-2. doi: 10.1016/j.urology.2014.06.001. PMID: 25168522
2. **Penson DF**. Learning to see the forest through the trees. Surgery. 2014 May;155(5):797-8. doi: 10.1016/j.surg.2014.01.008. PMID: 24787106
3. Morgans AK, **Penson DF**. The More, The Merrier: Including a Medical Oncologist in Treatment Planning for Localized Prostate Cancer. J Oncol Pract. 2014 Mar;10(2):113-4. doi: 10.1200/JOP.2013.001247. Epub 2014 Jan 7. PMID: 24399852
4. **Penson DF**. Time to raise the bar in localised prostate cancer. BJU Int. 2013 Aug;112(3):278. PMID: 23826836
5. **Penson, DF**. Accountable care organizations in surgery: location, location, location. JAMA Surg. 2013 Jun;148(6):554. PMID:23426580
6. **Penson, DF**. Post-prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem. Eur Urol. 2013 Nov;64(5):773-5. PMID: 23499365
7. **Penson DF**, Lange PH. Systemic therapy and the urologic oncologist: a unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient. Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S2-4. PMID: 22795076.

8. **Penson DF.** Treatment for postprostatectomy incontinence: is this as good as it gets? *JAMA*. 2011 Jan 12;305(2):197-8. PMID: 21224463.
9. **Penson DF.** Medicare reimbursement changes for bladder biopsies: a cautionary tale of unintended consequences. *Cancer*. 2010 Mar 1;116(5):1153-4. PMID: 20091840.
10. **Penson DF.** Laparoscopic Urological Oncology: Here come the Outcomes! *J Urol*. 2005 Oct;174(4 Pt 1):1174. PMID: 16145363.
11. **Penson DF.** Variations in prostate cancer patterns of care: Is it the quality of care or the quality of the data? *J Clin Oncol*. 2005 Nov 1;23(31):7783-4. Epub 2005 Oct 11. PMID: 16219931.
12. **Penson DF.** Laparoscopic Radical Prostatectomy: A Great Advance or a Costlier Version of the Same? *American Journal of Urology Review*, 2(7), 2004, 1-2.
13. **Penson DF.** Laparoscopic partial nephrectomy and prostatectomy: weighing the costs and the benefits. *J Urol*. 2004 Jul;172(1):6-7. PMID:15201726.
14. **Penson DF, Krieger, JN.** Men's health: Are we missing the big picture? *J Gen Intern Med*. 2001 Oct;16(10):717-8. PMID: 11679042. PMID: 1495275.

Letters to the editor

15. Singer EA, **Penson DF**, Palapattu GS. PSA screening and elderly men. *JAMA*. 2007 Mar 7;297(9):949; author reply 949-50. PMID: 17341705.
16. **Kapoor DA, Penson D.** Adhering to the standard of care for prostate cancer. *Health Aff (Millwood)*. 2012 Jun;31(6):1367.

Book Reviews

17. **Penson, D.F.:** Review of "Male Sexual Function: A guide to clinical management", J.J. Mulcahy, editor. *Annals of Internal Medicine* 137(4):300, 2002.

Book Chapters

18. Scales, CD, **Penson, DF:** Clinical Trials in Urology. In: Dahm, P and Dmochowski, RD, eds: *Evidence-Based Urology*. Oxford, UK: Blackwell Publishing, 12-17, 2010.
19. Huang, GJ, **Penson, DF:** Long-Term Outcomes of Radical Prostatectomy. In Taneja, SS, editor: *Complications of Urologic Surgery*. 4th ed., Philadelphia, PA: Saunders, 521-533, 2010.

20. **Penson, DF**, Albertsen, PC. The Natural History of Prostate Cancer. In: Albin, R.J. and Mason, M., editors. Metastasis of Prostate Cancer, Dordrecht, The Netherlands: Springer, 5-20, 2007.
21. Quek, ML, **Penson, DF**. Quality Of Life Instruments for Prostate Cancer. In: Partin, A., Parsons, K.L., editors. Prostate Cancer, London: Taylor & Francis, 683-6, 2006.
22. **Penson, DF**, Litwin, MS: Health-Related Quality of Life Issues in Urologic Oncology. In Richie, J.A. and D'Amico, A.V., eds.: Urologic Oncology. Philadelphia, Elsevier Saunders, 102-112, 2005.
23. **Penson DF**, Litwin MS: Health-related quality of life in female urinary incontinence. In Vasavada SP, Appell RA, Sand P, Raz S, eds., Female Urology, Urogynecology, and Voiding Dysfunction, New York: Marcel-Dekker, 53-64, 2005.
24. **Penson, DF**: Benign prostatic hyperplasia. In: Korenman, S., editor, Best Practice of Medicine: Endocrinology, [<http://praxis.md>]. New York: Praxis Press. 2001 December.
25. Etzioni, R **Penson, DF**. Mathematical issues in PSA testing. In: Thompson, I.M., Resnick M.I. and Klein, E.A., eds. Prostate Cancer Screening, Totowa, NJ, Humana Press, pp. 47-62, 2001.
26. **Penson, DF**, Litwin, MS. The Effect of Complications on Quality of life. In: Taneja, S., Smith, R.B. and Ehrlich, R., eds.: Complications of Urologic Surgery, 3rd ed., Philadelphia, PA, W.B. Saunders and Company, pp 56-66, 2000.
27. **Penson, DF**. Follow-up of patients with prostate cancer. In: Rose BD, editor, UpToDate. UpToDate, Wellesley, MA, 2000.
28. **Penson, DF**, Litwin, MS. Assessing Quality of Life: Surgery versus Radiation. In: Klein, E.A., editor: The Management of Prostate Cancer, Totowa, NJ, Humana Press, pp 183-198, 2000.
29. Litwin, MS, **Penson, DF**. Health-related Quality of Life and Genitourinary Malignancies. In: Beldegrun, A.S., Kirby, R.S., Oliver, T. eds.: New Prospectives in Prostate Cancer, Oxford, Isis Medical Media, Ltd., pp.391-401, 1998.
30. **Penson, DF**, Raz, S. Why anti-incontinence surgery succeeds or fails. In: Raz,S, editor: Female Urology, 2nd ed., Philadelphia, W. B. Saunders and Co., pp 435-445, 1996.

31. **Penson, DF**, Ng, C, Rajfer, J, Gonzalez-Cadavid, NF: Androgen dependence of neuronal nitric oxide synthase content and erectile function in the rat penis. In: Stamler, J., Gross, S., Moncada, S. and Higgs, H.E., editors: The Biology of Nitric Oxide, part 5. London, U.K., Portland Press Ltd., 1996, p. 245-246.

Books Editorships

32. **Penson, DF**, Wei, JT, eds.: Clinical Research Methods for Surgeons. Cleveland, Humana Press, Inc., 2006.
33. **Penson, DF**, Specialty Editor, in: Gomella, LG, ed.: The 5-Minute Urology Consult, 2nd Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2010

Guest Journal Editorships

34. Gilbert SM, **Penson, DF**, guest editors: Outcomes research in urology. World Journal of Urology. 2011 Feb; 29(1).
35. Evans, CP, **Penson, DF**, guest editors: Management of bladder cancer and urinary tract reconstruction: A Festschrift for John Stein. World Journal of Urology, 2009 Feb 27; (1).

G. MISCELLANY

Selected Visiting Professorships and Keynote Presentations

1. Richard L. Dunham Visiting Professorship, Albany Medical College Department of Urology, Albany, NY, June 19-20, 2014.
2. American Urological Association Annual Meeting State-of-the Art Lecture, Orlando, FL, April 20, 2014
3. Emory Urology Symposium, Keynote Presentation, Atlanta GA, December 7, 2013
4. New York University State-of-the Art meeting, New York, NY, December 6, 2013
5. Society of Urologic Oncology Winter Meeting Plenary Presentation, Washington, DC, December 5, 2013
6. American College of Surgeons Clinical Congress, Washington DC, October 9, 2013
7. Charles Higgins MD Lecture, Puerto Rico Urologic Society Annual Meeting, San Juan, PR, September 28, 2013
8. American Urological Association Annual Meeting Plenary Presentation, San Diego, CA May 5, 2013.

9. Society of Urologic Oncology Annual Meeting Plenary Presentation, San Diego, CA May 4, 2013
10. Japanese Urological Association Annual Meeting Keynote Address, Sapporo, Japan, April 27, 2013
11. Issues and Controversies in Prostate Cancer Care meeting, University of British Columbia, Vancouver Canada, February 28, 2013
12. Edgar Burns Visiting Professor, Louisiana State University Medical Center and Ochsner Clinic Departments of Urology Symposium, New Orleans, LA, January 1, 2013.
13. New York University State-of-the Art meeting, New York, NY, December 6, 2012
14. Visiting Professor, Huntsman Cancer Center Lecture Series, Salt Lake City, Utah, November 7, 2012
15. Institute for Cancer Outcomes Research and Evaluation, Fred Hutchinson Cancer Research Center, Seattle, WA, August 20, 2012.
16. 13th Annual Australasian Prostate Cancer Conference, Melbourne, Australia, August 1-3, 2012.
17. Russian Institute of Urology, Moscow, Russian Federation, June 18, 2012.
18. Russian Endourology Society, Rostov-on-Don, Russian Federation, June 15, 2012.
19. Marcia and Donald Pellar Visiting Professor, Department of Urology, Mayo Clinic-Scottsdale, Scottsdale, AZ, June 21-22, 2012.
20. Jackson Hole Urology Seminar, Jackson Hole, Wyoming, Feb 5-10, 2012.
21. University of Toronto Urology Update, Toronto, CA, Nov. 5-6, 2011.
22. Best of the American Urological Association Meeting, Tokyo, Japan, Sept 30-Oct. 3, 2011.
23. Best of the American Urological Association Meeting, Tokyo, Japan, Oct 16-17, 2010.
24. Institute for Clinical and Translational Sciences, Washington University, St Louis, MO, Sept 14-15, 2010.

25. Department of Urology, Virginia Mason Medical Center, Seattle, WA, April 21-23, 2010.
26. Department of Urology, Medical University of South Carolina, Charleston, SC, April 8-9, 2010.
27. Hans Schapira Visiting Professor, Department of Urology, Mount Sinai School of Medicine, New York, NY, May 20, 2009.
28. Department of Urology, University of Florida School of Medicine, Gainesville, Florida, January 28-30, 2009.
29. Section of Urology, Department of Surgery, Oregon Health Sciences University, June 8-10, 2006.
30. Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, May 28-30, 2003.
31. Department of Urology, Medizinische Hochschule Hannover, Hannover, Germany, February 27- March 3, 2000.
32. New York Section American Urological Association Valentine Essay Competition Judges Panel, March 24, 1999.

Other

1. Invited Speaker, "Factors Influencing Patients' Acceptance of and Adherence to Active Surveillance", NIH State-of-the-Science Conference on the Role of Active Surveillance in the Management of Men with Localized Prostate Cancer, Bethesda, MD, Dec. 5-7, 2011.
2. Reviewer, Prostate Cancer Control Initiative, Screening for Prostate Cancer Information Kit, Centers for Disease Control and Prevention, 2002.